On April 3, 2019, the European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400) covering CRISPR-Cas9 systems, edited cells, and the use of CRISPR-Cas9 in any environment (including plant, animal and human cells). This third European patent also includes claims covering CRISPR-Cas9 compositions for use in treating human and animal diseases.
In addition to this third patent, both the first and second European patents awarded to the Doudna-Charpentier team cover the use of CRISPR-Cas9 gene editing in a broad range of cellular and noncellular settings: EP Patent No. 2 800 811 covers all uses of the single-guide format of the Cas9 system, and EP 3 241 902 coves modified Cas9 that incorporates additional DNA-modulating functions such as the regulation of gene expression.